Promising Results for Depression Treatment with Microdosing LSD

MindBio Therapeutics Corp. (CSE) has recently unveiled promising durability data from its Phase 2A clinical trials, which tested MB22001, the company’s innovative self-administered, take-home microdose of Lysergic Acid Diethylamide (LSD), as a treatment for depression.

This development underscores MindBio’s commitment to advancing psychedelic medicine as a viable option for mental health treatment.

Read more

LSD, Psychosis and Healing

This study explores the paradoxical relationship connecting key parameters of the psychotic experience, psychotherapy, and psychedelic experience.

The link between psychosis model and therapeutic model seems to lie in mystical experiences.

The results point to the importance of meaning attribution for the LSD psychosis model and indicate that psychedelic-assisted therapy might benefit from therapeutic suggestions fostering mystical experiences.

Read more